Fas signaling in macrophages promotes chronicity in K/BxN serum-induced arthritis

Arthritis and Rheumatology

Volumn 66, Issue 1, 2014, Pages 68-77

  Huang, Qi Quan ^a   Birkett, Robert ^a   Koessler, Renee E ^a   Cuda, Carla M ^a   Haines III, G Kenneth ^b   Jin, Jian Ping ^c   Perlman, Harris ^a   Pope, Richard M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FAS ANTIGEN; GLYCOGEN SYNTHASE KINASE 3; GLYCOPROTEIN GP 96; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TOLL LIKE RECEPTOR 2; CXCL5 PROTEIN, MOUSE; ENDOPLASMIN; FAS PROTEIN, MOUSE; IL10 PROTEIN, MOUSE; MEMBRANE PROTEIN; TLR2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTHRITIS; ARTICLE; BONE MARROW CELL; CELL LINEAGE; CELL MIGRATION; CHRONICITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE DELETION; HISTOLOGY; MACROPHAGE ACTIVATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; CELL MOTION; CHRONIC DISEASE; EXPERIMENTAL ARTHRITIS; IMMUNOLOGY; MACROPHAGE; RHEUMATOID ARTHRITIS; SYNOVIUM; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD95; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL MOVEMENT; CHEMOKINE CXCL5; CHRONIC DISEASE; INTERLEUKIN-10; INTERLEUKIN-1BETA; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TOLL-LIKE RECEPTOR 2;

EID: 84897018315     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38198     Document Type: Article

References (48)

1. Gierut A, Perlman H, Pope RM. Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am 2010;36:271-96.
2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
3. Li J, Hsu HC, Yang P, Wu Q, Li H, Edgington LE, et al. Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model. Arthritis Rheum 2012;64:1098-109.
4. Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM. FLICE-inhibitory protein expression during macrophage differentiation confers resistance to fas-mediated apoptosis. J Exp Med 1999;190:1679-88. (Pubitemid 30002349)
5. Smith MD, Weedon H, Papangelis V, Walker J, Roberts-Thomson PJ, Ahern MJ. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology (Oxford) 2010;49:862-75.
6. Perlman H, Pagliari LJ, Liu H, Koch AE, Haines GK III, Pope RM. Rheumatoid arthritis synovial macrophages express the Fasassociated death domain-like interleukin-1β-converting enzyme-inhibitory protein and are refractory to Fas-mediated apoptosis. Arthritis Rheum 2001;44:21-30. (Pubitemid 32113114)
7. Jagger AL, Evans HG, Walter GJ, Gullick NJ, Menon B, Ballantine LE, et al. FAS/FAS-L dependent killing of activated human monocytes and macrophages by CD4βCD25γ responder T cells, but not CD4βCD25β regulatory T cells. J Autoimmun 2012;38:29-38.
8. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK, et al. The CD95 receptor: apoptosis revisited. Cell 2007;129:447-50. (Pubitemid 46660984)
9. Ma Y, Liu H, Tu-Rapp H, Thiesen HJ, Ibrahim SM, Cole SM, et al. Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation. Nat Immunol 2004;5:380-7. (Pubitemid 38500086)
10. Cuda CM, Agrawal H, Misharin AV, Haines GK III, Hutcheson J, Weber E, et al. Requirement of myeloid cell-specific Fas expression for prevention of systemic autoimmunity in mice. Arthritis Rheum 2012;64:808-20.
11. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell 1996;87:811-22. (Pubitemid 26404281)
12. Huang QQ, Koessler RE, Birkett R, Dorfleutner A, Perlman H, Haines GK III, et al. Glycoprotein 96 perpetuates the persistent inflammation of rheumatoid arthritis. Arthritis Rheum 2012;64:3638-48.
13. Scatizzi JC, Hutcheson J, Bickel E, Woods JM, Klosowska K, Moore TL, et al. p21Cip1 is required for the development of monocytes and their response to serum transfer-induced arthritis. Am J Pathol 2006;168:1531-41.
14. Scatizzi JC, Bickel E, Hutcheson J, Haines GK III, Perlman H. Bim deficiency leads to exacerbation and prolongation of joint inflammation in experimental arthritis. Arthritis Rheum 2006;54:3182-93. (Pubitemid 44622089)
15. Scatizzi JC, Hutcheson J, Bickel E, Haines GK III, Perlman H. Pro-apoptotic Bid is required for the resolution of the effector phase of inflammatory arthritis. Arthritis Res Ther 2007;9:R49.
16. Huang QQ, Sobkoviak R, Jockheck-Clark AR, Shi B, Mandelin AM II, Tak PP, et al. Heat shock protein 96 is elevated in rheumatoid arthritis and activates macrophages primarily via TLR2 signaling. J Immunol. 2009;182:4965-73.
17. Zhang Q, Lu Y, Proulx ST, Guo R, Yao Z, Schwarz EM, et al. Increased lymphangiogenesis in joints of mice with inflammatory arthritis. Arthritis Res Ther 2007;9:R118.
18. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 2010;11:936-44.
19. Petsch D, Anspach FB. Endotoxin removal from protein solutions. J Biotechnol 2000;76:97-119.
20. Huang Q, Ma Y, Adebayo A, Pope RM. Increased macrophage activation mediated through Toll-like receptors in rheumatoid arthritis. Arthritis Rheum 2007;56:2192-201. (Pubitemid 47173566)
21. Scatizzi JC, Hutcheson J, Pope RM, Firestein GS, Koch AE, Mavers M, et al. Bim-Bcl-2 homology 3 mimetic therapy is effective at suppressing inflammatory arthritis through the activation of myeloid cell apoptosis. Arthritis Rheum 2010;62:441-51.
22. Scatizzi JC, Mavers M, Hutcheson J, Young B, Shi B, Pope RM, et al. The CDK domain of p21 is a suppressor of IL-1β-mediated inflammation in activated macrophages. Eur J Immunol 2009;39:820-5.
23. Letellier E, Kumar S, Sancho-Martinez I, Krauth S, Funke-Kaiser A, Laudenklos S, et al. CD95-ligand on peripheral myeloid cells activates Syk kinase to trigger their recruitment to the inflammatory site. Immunity 2010;32:240-52.
24. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin 1 and tumor necrosis factor α in antibody-induced arthritis. J Exp Med 2002;196:77-85. (Pubitemid 34747313)
25. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997;61:375-80. (Pubitemid 27219829)
26. Cox JH, Starr AE, Kappelhoff R, Yan R, Roberts CR, Overall CM. Matrix metalloproteinase 8 deficiency in mice exacerbates inflammatory arthritis through delayed neutrophil apoptosis and reduced caspase 11 expression. Arthritis Rheum 2010;62:3645-55.
27. Croker BA, O'Donnell JA, Nowell CJ, Metcalf D, Dewson G, Campbell KJ, et al. Fas-mediated neutrophil apoptosis is accelerated by Bid, Bak, and Bax and inhibited by Bcl-2 and Mcl-1. Proc Natl Acad Sci U S A 2011;108:13135-40.
28. Steimer DA, Boyd K, Takeuchi O, Fisher JK, Zambetti GP, Opferman JT. Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. Blood 2009;113:2805-15.
29. Dzhagalov I, St John A, He YW. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood 2007;109:1620-6. (Pubitemid 46239596)
30. Wipke BT, Allen PM. Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis. J Immunol 2001;167:1601-8. (Pubitemid 32703161)
31. Jacobs JP, Ortiz-Lopez A, Campbell JJ, Gerard CJ, Mathis D, Benoist C. Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine model. Arthritis Rheum 2010;62:1921-32.
32. Pickens SR, Chamberlain ND, Volin MV, Gonzalez M, Pope RM, Mandelin AM II et al. Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization. Angiogenesis 2011;14:443-55.
33. Anderson SL, Shen T, Lou J, Xing L, Blachere NE, Srivastava PK, et al. The endoplasmic reticular heat shock protein gp96 is transcriptionally upregulated in interferon-treated cells. J Exp Med 1994;180:1565-9. (Pubitemid 24289632)
34. Chen YG, Ashok BT, Liu X, Garikapaty VP, Mittelman A, Tiwari RK. Induction of heat shock protein gp96 by immune cytokines. Cell Stress Chaperones 2003;8:242-8. (Pubitemid 37484718)
35. Huang QQ, Pope RM. The role of glycoprotein 96 in the persistent inflammation of rheumatoid arthritis. Arch Biochem Biophys 2013;530:1-6.
36. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009;15:774-80.
37. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7. (Pubitemid 38294612)
38. Page TH, Charles PJ, Piccinini AM, Nicolaidou V, Taylor PC, Midwood KS. Raised circulating tenascin-C in rheumatoid arthritis. Arthritis Res Ther 2012;14:R260.
39. Yao PM, Tabas I. Free cholesterol loading of macrophages induces apoptosis involving the fas pathway. J Biol Chem 2000;275:23807-13. (Pubitemid 30624666)
40. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994;179:1517-27. (Pubitemid 24129569)
41. Finnegan A, Kaplan CD, Cao Y, Eibel H, Glant TT, Zhang J. Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res Ther 2003;5:R18-24.
42. Johansson AC, Hansson AS, Nandakumar KS, Backlund J, Holmdahl R. IL-10-deficient B10. Q mice develop more severe collageninduced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol 2001;167:3505-12. (Pubitemid 32861456)
43. [published erratum appears in J Immunol 2002;169:6056]
44. Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996;39:495-503.
45. Corr M, Boyle DL, Ronacher LM, Lew BR, Van Baarsen LG, Tak PP, et al. Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon β in mice: implications for rheumatoid arthritis. Ann Rheum Dis 2011;70:858-63.
46. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20. (Pubitemid 30060920)
47. Van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, et al. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon β-1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:64-9. (Pubitemid 40075277)
48. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010;10:170-81.